Australia's most trusted
source of pharma news
Posted 23 September 2021 AM
While Sanofi's Libtayo was touted to potentially become the first PD-1 inhibitor approved for cervical cancer in Australia, new designations and determinations handed out by the TGA reveal MSD's Keytruda is closing in.
Keytruda has been approved in the US since 2018 for patients with recurrent or metastatic cervical cancer, although it had not been clear whether MSD would seek a similar indication locally until now.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.